Answers are grounded in this paper and cite their sources.
Clinical evaluation reveals differential chemotherapy sensitivity across breast cancer subtypes, highlighting greater responsiveness in basal-like and erbB2+ tumors.
The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers.
No takes yet. Share an insight, caveat, or question.
Rouzier et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: